TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, term pregnant female with a gestational age of 37-42 weeks (singleton)~* Undergoing a planned primary and uncomplicated caesarean section (CS) for their first born under regional anaesthesia~* Aged between 18 and 40 years (both inclusive)~* Ability to communicate well with the Investigator and to comply with the requirements of the entire study~* Willing to give informed consent in writing.~Exclusion Criteria:~* Being obese with BMI ≥35 before pregnancy~* History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder~* History of cervical cancer~* History of severe infection of the uterus~* Previous surgery of the cervix or uterus or any other (previous) condition that could interfere with the measurement of uterine contractility~* Any clinically significant abnormality following review of medical history, laboratory result and physical examination at screening as judged by the Investigator~* Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of any of the study medication~* Contraindications for oxytocin use~* Hypersensitivity to the active substances or to any of the excipients of the investigational product (test product or comparator drug)~* Present use or use within 30 days before the start of the study medication of one or more of the following medications: antihypertensive drugs, anti-coagulant therapy, medication that could affect myometrial contractility, sex steroids, prostaglandins and its analogues, inhalation anaesthetics, vasoconstrictors/sympathomimetics and caudal anaesthetics, vasopressin-like drugs~* Administration of any other investigational drug within 3 months before first dosing~* Tobacco use (smoking or snuffing), currently or within the last 6 months before screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin intravenous (Type: EXPERIMENTAL): single dose of intravenous (IV) oxytocin
- Oxytocin tablet (Type: EXPERIMENTAL): single dose of oxytocin tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the ICU of the AMC~* Intubated and mechanically ventilated~* Within 24 hours of initial diagnosis of ARDS~* Moderate or severe ARDS (according to the Berlin definition for ARDS)~Exclusion Criteria:~* Age \< 18 years~* Patients previously included in this study~* Patients participating in other interventional trials that could influence ventilator settings and ventilation parameters~* Patients with suspected or confirmed pregnancy~* Patients with increased (of \> 15 mmHg) or uncontrollable intracranial pressure~* Patients in whom esophageal pressure measurement is contra-indicated (severe bleeding diathesis, suspicion of or known pharyngeal or esophageal obstruction, esophageal ulcers, varices or strictures)~* Moribund patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional lung protective ventilation (Type: ACTIVE_COMPARATOR): Use of conventional lung protective ventilation, according to the ARDSnet guidelines
- INTELLiVENT-ASV (Type: ACTIVE_COMPARATOR): Use of INTELLiVENT-ASV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Neonates with ≥ 36 and \<44 weeks gestation with at least one of the following:~   * Apgar Score ≤ 5 at 10 minutes after birth~  * Continued need for resuscitation, including endotracheal or mask ventilation at 10 minutes after birth~  * Acidosis, defined as either umbilical cord pH or any arterial, venous, capillary pH within 60 minutes of birth pH ≤ 7.00~  * Acidosis, defined as base deficit ≥ 16 mmol/l in umbilical blood sample or any blood sample within 60 minutes of birth (arterial or venous).~2. The presence of moderate/severe encephalopathy defined as:~   * Altered state of consciousness (lethargy, stupor, coma) and at least one of the following:~     * Hypotonia~    * Abnormal reflexes including oculomotor or papillary abnormalities~    * Weak or absent suck reflex~    * Clinical seizures AND~  * Depression of the background pattern (lower margin≤ 5 µV meaning at least DNV or BS, CLV, FT) or the presence of seizure activity on the aEEG, registered for at least 30 minutes within 6h after birth.~3. Presence in hospital and ability to start treatment within 6h after birth.~4. Informed Consent Form signed before first study-related activity according to local law.~5. Receiving standard therapy without hypothermia.~Exclusion Criteria:~1. Major antenatally known- or congenital abnormalities, such as hernia diaphragmatica requiring ventilation.~2. Major antenatally known chromosomal abnormalities, such as trisomy 13 or 18 or neonates with evident syndromal appearances including brain dysgenesis.~3. Severe growth restriction with a birth weight below the 3rd percentile.~4. Inability to insert an indwelling catheter (umbilical venous catheter or percutaneously inserted central catheter, preferably multiple lumen).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- 2-Iminobiotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NSTE-ACS~* Male, 50-80 years old~* Female, postmenopausal age~Exclusion Criteria:~* Female, premenopausal age~* autoimmune disease~* infectious disease~* neoplasms~* diabetes~* chronic renal failure~* moderate or severe liver insufficiency~* GRACE risk score\>140~* ACS or cerebrovascular accidents in previous three months~* in-stent restenosis~* surgery or trauma in previous three months~* active bleeding~* fibrinolytic therapy within 24 hours before randomization~* need for oral anticoagulation therapy~* an increased risk of bradycardia~* drugs study hypersensitivity (including aspirin)~* co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent.~* Has a diagnosis of true or functional iron deficiency without anemia within 30 days of treatment on this protocol~  * Iron deficiency without anemia (normal Hgb \>/= 11.6 g/dL but ferritin \< 30 ng/mL)~ * Functional iron deficiency without anemia (ferritin \>30 ng/ml and iron saturation of \<50%)~* Has a clinical diagnosis of suspected epithelial ovarian cancer based on imaging studies, exam findings and laboratory values~* Participants must be planning to receive neoadjuvant chemotherapy for their cancer diagnosis (NACT is defined as chemotherapy prior to debulking surgery)~* Participants must be planning to undergo surgery for their cancer diagnosis~* Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to administration of first dose of IV iron sucrose. WOCBP is defined as patients who retain their reproductive structures and are not menopausal (defined as \> age 50 with no menses for at least 1 year)~* Participants of reproductive potential must agree to use effective birth control during study participation. Effective birth control is defined as any FDA approved contraceptive method~Exclusion Criteria:~* Currently taken any form of oral or intravenous iron therapy. Patients must have discontinued iron therapy \> 30 days from study entry~* Current untreated or unstable heart disease~* History of iron induced hypersensitivity or allergy~* History of leukemia, lymphoma, or other myelodysplastic disorders~* Prior diagnosis of hemochromatosis or hemoglobinopathy (e.g. thalassemia)~* Any subject with immediate requirement for radiotherapy~* Concomitant enrollment in another clinical trial interfering with endpoints on this study~* Any medical condition which could compromise participation in the study according to the investigator's assessment~* Female patient who is pregnant or breast-feeding~* Patients unwilling or unable to comply with the protocol or unable to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Iron Sucrose (Type: EXPERIMENTAL): Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients with biopsy proven pure chronic allograft injury due to CNI toxicity.~Exclusion Criteria:~1. 24 hour urine protein or spot urine protein/creatinine ratio \> 500 mg/day~2. Estimated glomerular filtration rate (eGFR) \< 30 ml/min by modification of Diet in Renal Disease( MDRD) or 24 hour urine collection~3. Patients with Donor-specific antibody (DSA) by Luminex (mean fluorescence intensity values \> 1,000)~4. Recipients of multiple organ transplants or ABO-incompatible allograft~5. Current panel reactive antibody (PRA) greater than 30 percent~6. Graft loss at randomization~7. Pregnant women~8. Previous history of acute rejection~9. Previous history of allergy or intolerance to Zortress or Myfortic~10. Platelet count less than 100,000~11. White Blood Cell (WBC) less than 3,000~12. Hb less than 9 g/dL or Htc less than 30%~13. Biopsy findings of~    * Chronic antibody mediated rejection~   * Acute rejection~   * Positive C4d staining~   * Interstitial infiltrates more than 25% of the area~   * Transplant glomerulopathy~   * Recurrent or de novo glomerular disease~   * Polyoma nephropathy or positive simian virus 40 (SV40) staining

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Zortress) (Type: EXPERIMENTAL): None
- Reduced dose Tacrolimus (Prograf) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of the Quality of Life in Patients Operated With a Total Knee Prosthesis (TKA) From the FHK® Range.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject implanted with FHK® prosthesis in one of the following indication according to the instructions for use: knee disorders; Aseptic condylar necrosis.~* Subject who received an information form and is willing to participate in the study.~* Adults subjects (≥18 years old).~* Access to an internet connection allowing to complete the questionnaires on the online platform~Exclusion Criteria:~* Contraindications described in the instructions for use~* Subject who is not able to express his/her non-opposition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients receiving a prosthesis from the FHK® range (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as mild to moderate COVID-19 infection with positive PCR test and symptoms (Ct \< 35)~* Parents and patients comprehend and welling to participate in this study.~* Agree to the collection of nasal swabs per day as protocol.~Exclusion Criteria:~* Patients evaluated as severe or critically severe type of COVID-19 infection (Individuals who have SpO2 \<94% on room air, oxygen treatment is necessary, respiratory failure, septic shock, and/or multiple organ dysfunction).~* Patients with comorbidities~* Decline to participate by parents or children~* Allergy to any study medication or usage of any kind of interferon treatment within 14 days before test~* Children cannot tolerate the inhalation treatment~* Any situation where the program cannot be carried out safely.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention: Inhaled Interferon α2b (Type: EXPERIMENTAL): Inhaled Interferon α2b (10U/ml)
- Intervention: Standard of Care (Type: OTHER): Standard of care treatment will be provided according to management guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of FSGS.~* Patients with a proteinuria ≥ 3.5g/24h,and blood albumin \<30g/L,and Scr\< 2.3 mg/dl and eGFR\>30ml/min per 1.73m2.~* Patients who signed written informed consent form (patients less than 18 years old with their parents/legal representative's signatures), and have given their consent to follow all study procedures and follow-up.~Exclusion Criteria:~* Patients who have received treatment of FK506 in latest 2 month or the cumulative dose CTX≥6 g.~* Patients who are known to be allergic to a macrolide.~* Patients who have active hepatitis.~* Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit .~* Patients with blood leukocyte \< 3000/ul.~* Patients with kidney disease family history~* Patients with 2 type diabetes.~* Patients with obesity whose BMI\>28kg/m2.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: ACTIVE_COMPARATOR): CTX
- FK506 (Type: EXPERIMENTAL): 0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 18-80~* Diagnosis of large-duct PSC based on ERCP or MRCP, or liver biopsy findings without alternative explanation for findings, for at least 6 months.~* Serum ALP levels persistently more than 1.5 x upper limit of normal over the past 6 months.~* Ursodeoxycholic acid therapy must be discontinued for at least 3 months.~* At least 2 forms of barrier protection for males and females of child-bearing age.~Exclusion Criteria:~* Small duct PSC, overlap with autoimmune hepatitis, IgG4 disease or secondary sclerosing cholangitis.~* Any malignancy, presently or within the past 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix or in situ prostate cancer.~* Viral hepatitis including hepatitis A, B, C, D, E.~* Decompensated cirrhosis, or planned liver transplantation.~* Recent diagnostic or therapeutic biliary manipulation (endoscopic, radiologic) within the past 3 months.~* Ascending Cholangitis requiring antibiotics within the past 3 months.~* Uncontrolled IBD, or IBD requiring the use of steroids.~* Acute or Chronic Kidney Disease with serum creatinine \> 2 mg/dL.~* Allergy to ATRA or vitamin A compounds.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- All-trans retinoic acid (ATRA) therapy (Type: EXPERIMENTAL): Fixed low dose of ATRA 10 mg twice daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~Key Inclusion Criteria:~* Aged \>= 18 years old at the time of informed consent.~* Histologically confirmed follicular Grade 1-3a NHL.~* Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.~* Bidimensionally measurable disease with at least 1 lesion \>= 2.0 cm in a single dimension.~* Acceptable hematologic, hepatic, and renal function parameters.~* Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs.~Key Exclusion Criteria:~* Follicular lymphoma Grade 3b.~* Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior rituximab or prior rituximab-containing regimen, or a response with a TTP of less than 6 months).~* Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosourea or mitomycin C).~* Prior lymphoma vaccine therapy within 12 months prior to Study Day 1.~* Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1.~* Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1.~* Prior allogeneic transplant.~* Transfusion-dependent subjects.~* Another primary malignancy requiring active treatment (except hormonal therapy).~* Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions, which would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.~* New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues